# Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration

> **NCT05953012** · PHASE1 · COMPLETED · sponsor: **PharmAbcine** · enrollment: 17 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **DRUG:** PMC-403

## Key facts

- **NCT ID:** NCT05953012
- **Lead sponsor:** PharmAbcine
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-20
- **Primary completion:** 2025-08-22
- **Final completion:** 2025-12-17
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2025-12-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05953012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05953012, "Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05953012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*